The vial form of Remdesivir (Desrem) is still imported. We are producing Oseltamivir 75 mg in capsule form in the country.
Jakarta (ANTARA) - PT Indofarma is pursuing the production target of COVID-19 therapeutic drugs -- Remdesivir, Oseltamivir, and Ivermectin -- to be achieved during the July-September 2021 period in Indonesia.

“The vial form of Remdesivir (Desrem) is still imported. We are producing Oseltamivir 75 mg in capsule form in the country,” PT Indofarma President Director, Arief Pramuhanto, stated during a hearing (RDP) with the House of Representatives’ Commission VI held virtually here on Wednesday.

Remdesivir is still obtained through imports from India, and as many as 140 thousand vials are scheduled to arrive here on Sunday (July 11), he confirmed.

The additional 90 thousand vials will also arrive on Thursday (July 15), he noted.

“Collectively, we will receive 230 thousand vials by this month. One vial is for one inoculation,” he stated.

For the Oseltamivir type, Indofarma will produce approximately five million capsules per month until August and September 2021, Pramuhanto noted.

“We have prepared to produce eight million capsules or about 80 thousand boxes of Oseltamivir,” he stated.

Such medicines have been scheduled to be produced due to the current surge in demand, he informed.

PT Indofarma is also boosting its production capacity of the Ivermectin type of therapeutic drug for COVID-19 patients, doubling from the production in July 2021 of as many as eight million pills.

“During this month, up to eight million pills or approximately 400 thousand vials of Ivermectin will be produced, and next month, we will add some facilities to help double its production,” he remarked. Related news: COVID surge: SOE Minister assures of availability of antiviral drugs
Related news: Govt secures COVID-19 medicine availability till year end


Translator: Andi Firdaus/ Juwita Trisna
Editor: Suharto
Copyright © ANTARA 2021